DrugPatentWatch Database Preview
NETSPOT Drug Profile
Which patents cover Netspot, and what generic alternatives are available?
Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-three patent family members in eighteen countries.
The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.
Summary for NETSPOT
| International Patents: | 23 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 3 |
| DailyMed Link: | NETSPOT at DailyMed |
Generic Entry Opportunity Date for NETSPOT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for NETSPOT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aaa Usa Inc | NETSPOT | gallium dotatate ga-68 | POWDER;INTRAVENOUS | 208547-001 | Jun 1, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Aaa Usa Inc | NETSPOT | gallium dotatate ga-68 | POWDER;INTRAVENOUS | 208547-001 | Jun 1, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Aaa Usa Inc | NETSPOT | gallium dotatate ga-68 | POWDER;INTRAVENOUS | 208547-001 | Jun 1, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
